Prostate cancer is a major health concern for men and the people who support them. The American Cancer Society (ACS) estimates 333,830 new U.S. cases and 36,320 deaths in 2026. These estimates, along with National Cancer Institute (NCI) and SEER measures from specific periods, help caregivers understand the scale and variation of the disease.
Contents
- The national picture
- Incidence and mortality rates
- Differences by race and ethnicity
- Age and the caregiver experience
- Stage and survival
- Trends and selected states
The national picture
The ACS estimates that 333,830 men in the United States will be diagnosed with prostate cancer in 2026. It estimates that 36,320 men will die from the disease during the same year. Because these are forecasts for 2026, they should be understood as estimates rather than completed counts. (American Cancer Society, [Key Statistics for Prostate Cancer])
Prostate cancer accounts for 30% of all cancers in males, according to the NCI’s Prostate Cancer Screening PDQ. It accounts for 11% of cancer-related deaths in males in the same NCI source. Those shares place prostate cancer among the most consequential diagnoses families may encounter while arranging treatment, transportation, appointments, and daily support.
SEER estimates that 3,700,086 men were living with prostate cancer in the United States in 2023. This number includes men at different stages of care and recovery, not only people receiving active treatment. A large living population means that caregiver needs can arise during diagnosis, treatment, surveillance, recurrence, rehabilitation, or long-term survivorship. (SEER Cancer Stat Facts: Prostate Cancer)
The ACS estimated 299,010 new prostate cancer cases among U.S. men in 2024 and 35,250 prostate cancer deaths in 2024. Prostate cancer represented 29% of estimated new male cancer cases that year. These 2024 figures are historical ACS estimates for that year, while the 2026 figures above are later estimates; they should not be treated as a single-year count. (ACS, Leading Sites of New Cancer Cases and Deaths, 2024)
Incidence and mortality rates
Rates allow comparisons across populations of different sizes. The NCI reports a U.S. age-adjusted prostate cancer incidence rate of 105.0 per 100,000 men in 2022. Its age-adjusted mortality rate was 18.7 per 100,000 men in 2022. Age adjustment helps make populations with different age structures more comparable. (NCI Prostate Cancer Screening PDQ)
SEER reports a prostate cancer death rate of 18.9 per 100,000 men per year based on data from 2020–2024. The period and rate are slightly different from the NCI’s single-year 2022 measure, so the two figures should be read as separate reporting windows rather than combined. (SEER Cancer Stat Facts: Prostate Cancer)
The lifetime risk of being diagnosed with prostate cancer is about 13.2%, according to SEER. Put another way, the statistic describes the estimated chance of a diagnosis over a man’s lifetime, not the chance of dying from the disease or the risk in one particular year. (SEER Cancer Stat Facts: Prostate Cancer)
For caregivers, incidence and mortality answer different questions. Incidence describes new diagnoses; mortality describes deaths. A high incidence rate does not mean that the same proportion of diagnosed men will die, and survival statistics add important context about what happens after diagnosis.
Differences by race and ethnicity
The NCI reports a 2022 prostate cancer mortality rate of 17.9 per 100,000 for White men and 36.4 per 100,000 for Black men. These are age-adjusted rates for that year. (NCI Prostate Cancer Screening PDQ)
SEER’s 2020–2024 death rates also show substantial differences among racial and ethnic groups. The rate was 36.2 per 100,000 for non-Hispanic Black men and 18.1 per 100,000 for non-Hispanic White men. It was 15.0 per 100,000 for Hispanic men, 17.4 per 100,000 for non-Hispanic American Indian/Alaska Native men, and 8.7 per 100,000 for non-Hispanic Asian/Pacific Islander men. (SEER Cancer Stat Facts: Prostate Cancer)
| Group | Prostate cancer death rate | Measurement period or year |
|---|---|---|
| Black men | 36.4 per 100,000 | NCI, 2022 |
| White men | 17.9 per 100,000 | NCI, 2022 |
| Non-Hispanic Black men | 36.2 per 100,000 | SEER, 2020–2024 |
| Non-Hispanic White men | 18.1 per 100,000 | SEER, 2020–2024 |
| Hispanic men | 15.0 per 100,000 | SEER, 2020–2024 |
| Non-Hispanic American Indian/Alaska Native men | 17.4 per 100,000 | SEER, 2020–2024 |
| Non-Hispanic Asian/Pacific Islander men | 8.7 per 100,000 | SEER, 2020–2024 |
These figures describe population patterns, not an individual man’s prognosis. A caregiver can use them as context for conversations with a clinical team, while relying on the patient’s stage, test results, overall health, and treatment plan for personal decisions.
Age and the caregiver experience
SEER reports that the median age at prostate cancer death is 79. The distribution of prostate cancer deaths is concentrated at older ages: 34.7% occurred among men aged 75–84, 31.0% among men older than 84, and 24.9% among men aged 65–74. Deaths among men aged 55–64 represented 8.3%. (SEER Cancer Stat Facts: Prostate Cancer)
The remaining reported shares were 1.0% for ages 45–54, 0.1% for ages 35–44, and 0.0% for ages 20–34 and for men under 20. These percentages describe the distribution of prostate cancer deaths, not the probability that a person in each age group will die from prostate cancer.
Age can shape practical support needs. An older adult may be coordinating cancer care alongside other health conditions, mobility limitations, medication routines, or a spouse’s needs. A younger patient or family may face different work, childcare, or financial pressures. The statistics do not prescribe a caregiving plan, but they show why support should be tailored to the person rather than based on a single average.
Stage and survival
SEER reports a 5-year relative survival rate of 98.2% for prostate cancer overall. Relative survival compares observed survival with survival expected for similar people in the general population; it is a population statistic and does not predict one patient’s outcome. (SEER Cancer Stat Facts: Prostate Cancer)
Survival varies by stage at diagnosis. Localized prostate cancer has a 5-year relative survival rate of 100.0%, and regional prostate cancer also has a rate of 100.0%. Distant prostate cancer has a rate of 40.1%, while unstaged prostate cancer has a rate of 94.1%. (SEER Cancer Stat Facts: Prostate Cancer)
| Stage at diagnosis | Share of diagnoses | 5-year relative survival |
|---|---|---|
| Local | 69.5% | 100.0% |
| Regional | 14% | 100.0% |
| Distant | 9% | 40.1% |
| Unstaged | 8% | 94.1% |
About 69.5% of prostate cancers are diagnosed at the local stage, 14% at the regional stage, 9% at the distant stage, and 8% are unstaged at diagnosis. The stage categories and survival figures belong together: stage describes how far the cancer has spread when diagnosed, while survival describes outcomes across groups followed over time.
For a caregiver, the stage discussion can clarify why appointments, imaging, treatment, symptom management, and follow-up differ from one person to another. A survival percentage should not be used to forecast a specific patient’s future without the treating team’s interpretation.
Trends and selected states
SEER reports that age-adjusted prostate cancer incidence rates rose by an average of 2.7% per year from 2014 through 2023. It also reports that age-adjusted death rates fell by an average of 0.8% per year from 2015 through 2024. These are average annual trends across the stated periods, not a claim that every individual year moved by exactly the same amount. (SEER Cancer Stat Facts: Prostate Cancer)
The ACS reported the following estimated prostate cancer deaths in 2024: 4,790 in Texas, 4,070 in Florida, 3,010 in New York, 2,400 in Pennsylvania, and 1,560 in Georgia. These are state-level estimates, not observed counts, and larger states may have larger totals simply because more people live there. (ACS Cancer Facts & Figures 2024)
State incidence rates reported by the ACS for 2016–2020 also varied: 120.3 per 100,000 men in Alabama, 95.4 in California, 97.0 in Florida, 134.7 in Georgia, 130.3 in New York, and 104.1 in Texas. These rates cover a five-year period and should not be directly substituted for the national 2022 rate. (ACS Cancer Facts & Figures 2024)
The combination of rising incidence in the 2014–2023 SEER trend, falling mortality in the 2015–2024 trend, and high overall relative survival illustrates why prostate cancer statistics need several measures. New diagnoses, deaths, stage, survival, age, race and ethnicity, and geography each describe a different part of the experience. For families providing care, that fuller context can support clearer questions about the diagnosis and the help needed at each stage of treatment.